Dr. Jared Gardner presents a discussion on challenging soft tissue pathology cases that frequently result in misdiagnosis or confusion with malignancy. The presentation details three main entities: Massive Localized Lymphedema (MLL), Spindle Cell Lipoma (SCL), and Pleomorphic Lipoma (PL), contrasting them with liposarcoma and dermatofibrosarcoma protuberans (DFSP).
The first case analyzes MLL, emphasizing how the clinical context (morbid obesity, bilateral masses) and microscopic findings (widened, edematous, fibrotic septa while retaining lobular fat architecture) differentiate it from Atypical Lipomatous Tumor (ALT). The second section explores SCL, particularly its low-fat, mixoid variant, highlighting the importance of recognizing subtle palisading of bland spindle cells and ropey collagen, and utilizing RB1 loss (via immunostain or FISH) to distinguish it from DFSP. A brief interlude discusses challenging Mixoid DFSP which lacks the classic storiform pattern but retains key cytological features. Finally, the presentation reviews Pleomorphic Lipoma, noting its demographic preference and characteristic benign yet pleomorphic 'floret-like' giant cells.
Soft Tissue Pathology Cases: Mimics of Malignancy
0:30 Case 1: Massive Localized Lymphedema (MLL): A 10 cm thigh mass in a 50-year-old morbidly obese woman, initially raising concern for a neoplasm.
Low Power Clues (0:37): Mature fat with thick, pale (mixoid/edematous) septation and prominent vascularity, mimicking Well-Differentiated Liposarcoma (WDL)/Atypical Lipomatous Tumor (ALT).
4:32 Key Clinical Takeaway: MLL should be strongly considered in morbidly obese patients presenting with large, often bilateral masses in the inner thigh or genital area.
6:41 Pathological Hallmark: Chronic edema leads to significantly widened, edematous, and fibrotic fibrous septa in the subcutis, but the fat retains its normal lobular architecture (unlike WDL/ALT).
11:17 Secondary Changes: Areas show features of fat atrophy (shrunken adipocytes, folded cell membranes, increased vessel density), and the dermis exhibits sclerosis, edema, and ectatic lymphatic channels.
21:31 Malignancy Risk: Chronic lymphedema, like post-radiation changes, is associated with a long-term risk of developing Angiosarcoma.
24:49 Case 2: Spindle Cell Lipoma (SCL): A subcutaneous mass on the trunk/back, presenting with mixoid background, bland spindle cells, and thick collagen bundles, with trapped fat.
28:47 Differential Diagnosis: The features (CD34 positivity, fat entrapment, mixoid stroma) necessitate differentiation from Dermatofibrosarcoma Protuberans (DFSP).
30:01 Key SCL Clue: Subtle palisading or parallel arrays of bland spindle cells, giving a vaguely neural appearance.
33:37 SCL Triad: Bland spindle cells (often palisading), mature fat (variable amounts), and ropey collagen bundles.
33:04 Molecular Takeaway: SCL often shows loss of one copy of the RB1 gene (Retinoblastoma), which can be detected by IHC (loss of nuclear expression) or FISH, aiding differentiation from DFSP.
38:07 SCL Variant: Presentation includes the pseudoangiomatous (or angiomatous) pattern of SCL, characterized by large, dilated, cleft-like spaces.
41:10 Mixoid DFSP (Differential Point): Discussion of a rare, challenging mixoid DFSP lacking the classic storiform pattern.
DFSP Clues (41:46): Presence of triangle-shaped (stellate) cells and multinucleated tumor giant cells (resembling the Giant Cell Fibroblastoma variant), along with peripheral honeycomb fat entrapment.
45:40 Molecular Tool: DFSP is confirmed by FISH detecting the COL1A1-PDGFB translocation.
47:18 Case 4: Pleomorphic Lipoma (PL): A fatty tumor from the upper back of a 50-year-old man (classic site and demographic).
48:36 Key PL Feature: Contains all features of SCL (fat, mixoid stroma, ropey collagen) plus the addition of atypical, pleomorphic, multinucleated cells arranged in a characteristic floret-like pattern.
50:06 Takeaway: PL and SCL are benign entities on the same spectrum. Despite the "scary looking" pleomorphism, PL is a benign diagnosis that typically does not require further treatment, though molecular testing (RB1/MDM2) may be needed if deep/large or in unusual locations (DDx: WDL/ALT).